Mesa Laboratories Inc (MLAB) financials
Mesa Laboratories revenue and earnings by year
Mesa Laboratories's revenue was $249 million in the fiscal year to March 31, 2026, up 3.4% from the year before. Net income was $6.71 million, 2.7% of revenue. Since the fiscal year to March 31, 2017, revenue has grown 11.5% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 249 | 241 | 216 | 219 | 184 | 134 | 118 | 103 | 96 | 94 |
| Revenue growth | 3.4% | 11.5% | -1.3% | 18.8% | 37.6% | 13.8% | 14.1% | 7.2% | 2.7% | — |
| Gross profit | 158 | 151 | 133 | 134 | 109 | 87 | 65 | 61 | 55 | 53 |
| Gross margin | 63.5% | 62.6% | 61.6% | 61.0% | 59.2% | 65.0% | 55.5% | 59.1% | 56.8% | 56.8% |
| Operating income | 19 | 16 | -272 | 3 | 7 | 12 | 8 | 10 | 2 | 16 |
| Operating margin | 7.4% | 6.8% | -125.9% | 1.5% | 4.0% | 9.2% | 6.7% | 9.5% | 2.2% | 17.4% |
| Net income | 7 | -2 | -254 | 1 | 2 | 3 | 2 | 7 | -3 | 11 |
| Net margin | 2.7% | -0.8% | -117.6% | 0.4% | 1.0% | 2.4% | 1.5% | 7.3% | -3.1% | 11.9% |
| Diluted EPS | $1.21 | -$0.36 | -$47.20 | $0.17 | $0.35 | $0.62 | $0.47 | $1.86 | -$0.86 | $2.91 |
| Free cash flow | 40 | 43 | 42 | 23 | 35 | 35 | 26 | 30 | 24 | 6 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open MLAB in Markets.
How Mesa Laboratories makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Sterilization & Disinfection Control | $24.5M | 40.7% |
| Calibration Solutions | $13.3M | 22.1% |
| Biopharmaceutical Development | $12.1M | 20.1% |
| Clinical Genomics | $10.3M | 17.1% |
See also: MLAB valuation and P/E history · MLAB returns
No forecast, no recommendation. This page describes Mesa Laboratories Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.